TUBERCULOSIS WITH CONCURRENT HIV INFECTION IN RUSSIA: STATISTICS AND CORRELATIONS
https://doi.org/10.21292/2075-1230-2018-96-12-9-17
Abstract
The objective of the study is to analyze TB/HIV co-infection situation in the regions of RF and to identify correlated epidemiological rates.
Subjects and methods. The data from Rosstat Forms no. 61, 8 and 33 were used as well as Rosstat data on the number of population for 2017.
The data reflecting the structure of the patients with TB/HIV co-infection were obtained from Rosstat Form no. 61 for 2017.
In order to define correlations between the rates characterizing the population of tuberculosis patients and patients with TB/HIV co-infection, the correlation analysis was performed (the standard tools of Statistica software).
Results of the study. In Russia, TB/HIV co-infection was not equally prevalent and it was the highest in 35 regions of Russia. According to the results of correlation analysis, in 37 RF regions with a low level of TB/HIV co-infection (< 7% of the total number of tuberculosis patients), tuberculosis mortality during the 1st year of follow-up depended on the prevalence of multiple drug resistant tuberculosis (MDR TB) among all tuberculosis patients. In 48 Russian regions with a high level of TB/HIV co-infection (≥ 7% of the total number of tuberculosis patients), the prevalence of MDR TB and mortality in the patients within the 1st year of follow up directly depended on the prevalence of this co-infection. In 16 Russian regions, where the portion of new cases with concurrent MDR TB made from 23 to 60%, the risk of lethal outcome was the highest. The co-morbidity with hepatitis was observed in 42% of new cases of co-infection and in 43% of all those being followed-up.
About the Authors
E. B. Tsybikova
Federal Research Institute for Health Organization and Informatics
Russian Federation
Russian Federation
Doctor of Medical Sciences, Chief Researcher of Department for Public Health Statistical Analysis
11, Dobrolyubova St., Moscow, 127254
+7 (495) 619-38-40.
V. V. Punga
Central Tuberculosis Research Institute
Russian Federation
Russian Federation
Doctor of Medical Sciences, Professor, Chief Researcher of Research and Organizational Department
2, Yauzskaya Alleya, Moscow, 107564
+7 (499) 785-91-87
cniitramn@yandex.ru
L. I. Rusakova
Central Tuberculosis Research Institute
Russian Federation
Russian Federation
Doctor of Medical Sciences, Head of Research and Organizational Department
2, Yauzskaya Alleya, Moscow, 107564
+7 (499) 785-91-87
cniitramn@yandex.ru
References
1. Lecheniye tuberkuleza: rekomendatsii. [Guidelines for treatment of tuberculosis]. 4th revision, WHO, Geneva, 2011, 183 p.
2. Punga V.V., Tsybikova E.B., Yakimova M.А., Izmaylova T.V. Treatment outcomes for tuberculosis cases with concurrent HIV infection. Socialnye Aspekty Zdorovya Naseleniya, 2017, no. 1 (53), Epub., Available at: http://vestnik.mednet.ru/content/category/5/90/30/lang,ru/ (In Russ.)
3. Raviglione M.K., Korobitsyn A.A. End TB – The new WHO strategy in the SDG era, and the contributions from the Russian Federation. Tuberculosis and Lung Diseases, 2016, vol. 94, no. 11, pp. 7-15. (In Russ.)
4. Rukovodstvo po lecheniyu tuberkuleza s mnozhestvennoy lekarstvennoy ustoychivostyu. [Guidelines on treatment of multiple drug resistant tuberculosis]. Partners in Health, 2003, 173 p.
5. Getahun H. et al. HIV infection associated tuberculosis: the epidemiology and the response. Clin. Infect. Dis., 2010, vol. 50, pp. 201-207.
6. Goletti D., Weissman D., Jackson R.W. et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. Immunol., 1996, vol. 157, no. 3, pp. 1271-1278.
7. Guelar A., Gatell J.M., Verdejo J. et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS, 1993, vol. 7, no. 10, pp. 1345-1349.
8. Sonnenberg P., Murray J., Glynn J.R. et al. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet, 2001, vol. 358 (9294), pp. 1687-1693.
9. Tuberculosis surveillance and monitoring in Europe 2018. WHO, 2018, 141p. Available at: http://www.euro.who.int/__data/assets/pdf_file/0010/364663/tb-report-2018.pdf
10. Waismann J.I., Palmero D.J., Albert F.A., Guemes Gurtubay J.L., Francos J.L., Negroni R. Improved prognosis in HIV/AIDS related multidrug resistant tuberculosis patients treated with highly active antiretroviral therapy. Medicina, 2001, vol. 61, no. 6, pp. 810-814.
11. Whalen C., Horsburgh C.R., Horn D., Lahart C., Simberkoff M., Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am. J. Respir. Crit. Care Med., 1995, vol. 151, no. 1, pp. 129-135.
12. WHO Three Is Meeting: Intensified case funding (ICF), Isoniazid preventive therapy (IPT) and TB Infection control (IC) for people living with HIV. Report of a joint WHO HIV/AIDS and TB department meeting. Geneva, WHO, 2008. Available at: http://who.int/hiv/pub/meeting-reports/WHO_3Is_meeting_report.pdf
Review
For citations:
Tsybikova E.B., Punga V.V., Rusakova L.I. TUBERCULOSIS WITH CONCURRENT HIV INFECTION IN RUSSIA: STATISTICS AND CORRELATIONS. Tuberculosis and Lung Diseases. 2018;96(12):9-17. (In Russ.) https://doi.org/10.21292/2075-1230-2018-96-12-9-17
Views:
1886
Email this article 